BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications

Despite chemotherapy and novel androgen-receptor signalling inhibitors (ARSi) have been approved during the last decades, metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease with poor clinical outcomes. Several studies found that germline or acquired DNA damage repair (D...

Descripción completa

Detalles Bibliográficos
Autores principales: Messina, Carlo, Cattrini, Carlo, Soldato, Davide, Vallome, Giacomo, Caffo, Orazio, Castro, Elena, Olmos, David, Boccardo, Francesco, Zanardi, Elisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492871/
https://www.ncbi.nlm.nih.gov/pubmed/32963528
http://dx.doi.org/10.1155/2020/4986365

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492871/
https://www.ncbi.nlm.nih.gov/pubmed/32963528
http://dx.doi.org/10.1155/2020/4986365

Ejemplares similares